Valuation: Exelixis, Inc.

Market Cap 14.53B 12.82B 12.13B 11B 20.63B 1,394B 20.84B 146B 56.1B 712B 54.57B 53.38B 2,292B P/E 2026 *
18.1x
P/E 2027 * 15x
Enterprise Value 13.79B 12.17B 11.51B 10.44B 19.57B 1,323B 19.77B 138B 53.23B 676B 51.77B 50.65B 2,174B EV / Sales 2026 *
5.4x
EV / Sales 2027 * 4.44x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day+0.85%
1 week+0.86%
Current month+7.34%
1 month+7.71%
3 months+8.05%
6 months+41.22%
Current year+33.81%
1 week 56.58
Extreme 56.58
59.12
1 month 53.43
Extreme 53.4283
59.72
Current year 39.71
Extreme 39.71
59.72
1 year 33.76
Extreme 33.755
59.72
3 years 18.64
Extreme 18.64
59.72
5 years 14.87
Extreme 14.87
59.72
10 years 10.04
Extreme 10.04
59.72
Manager TitleAgeSince
Chief Executive Officer 65 22/07/2010
Director of Finance/CFO 58 15/07/2015
Chief Operating Officer 63 01/02/2016
Director TitleAgeSince
Director/Board Member 70 01/02/2004
Director/Board Member 82 01/08/2004
Chairman 77 01/01/1998
Date Insider Type Main position Quantity % Market Cap. Importance
10/8/26 Sell

Director

-9,812 0.0039%
1/6/26 Sell

Director

-9,812 0.0039%
1/6/26 Sell

Director

-3,925 0.0016%
Change 5-day change 1-year change 3-year change Capi.($)
+0.48%+0.86%+44.56%+168.42% 14.53B
-0.70%-4.28%+52.62%+86.42% 71.53B
+0.92%+2.46%+38.76%+83.38% 60.12B
-0.60%+3.17%+9.94%+37.84% 48.85B
-0.73%-0.41%+48.84%+36.72% 44.28B
+1.36%+6.03%+343.85%+638.73% 43.83B
-0.47%-0.76%+9.75%+103.07% 41.53B
+0.34%+0.22%+5.18%+47.36% 30.13B
+4.77%+6.16%+36.77%+26.10% 27.98B
-1.73%-4.30%-18.37%+357.94% 25.25B
Average +0.38%+0.03%+57.19%+158.60% 40.8B
Weighted average by Cap. +0.22%-0.12%+62.70%+148.49%

Financials

2026 *2027 *
Net sales 2.55B 2.25B 2.13B 1.93B 3.63B 245B 3.66B 25.59B 9.86B 125B 9.59B 9.38B 403B 2.91B 2.56B 2.43B 2.2B 4.13B 279B 4.17B 29.11B 11.22B 142B 10.91B 10.67B 458B
Net income 821M 724M 685M 621M 1.17B 78.75B 1.18B 8.22B 3.17B 40.21B 3.08B 3.01B 129B 1.01B 893M 845M 767M 1.44B 97.14B 1.45B 10.14B 3.91B 49.6B 3.8B 3.72B 160B
Net Debt -744M -657M -622M -564M -1.06B -71.44B -1.07B -7.46B -2.87B -36.48B -2.8B -2.73B -117B -1.62B -1.43B -1.35B -1.23B -2.3B -156B -2.33B -16.25B -6.26B -79.51B -6.09B -5.96B -256B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
29/09/26 USD 58.65 +0.48% 2,244,178
28/09/26 USD 58.37 +0.36% 1,278,704
25/09/26 USD 58.16 +0.36% 1,989,681
24/09/26 USD 57.95 +2.15% 1,925,760
23/09/26 USD 56.73 -2.44% 1,431,534
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
58.65USD
Average target price
53.93USD
Spread / Average Target
-8.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock